Protara Therapeutics, Inc. announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, and where he maintains a faculty appointment. Dr. Bandari joined Protara in April 2020 as Vice President, Head of Clinical Development, and most recently was Interim Chief Medical Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.71 USD | +11.08% | +31.10% | +97.86% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+97.86% | 68.73M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- TARA Stock
- News Protara Therapeutics, Inc.
- Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer